Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | IKBKB | O14920 | 2/20 | 0.38 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 4/20 | 0.36 |
| ▸ | SCD | O00767 | 2/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 3/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12178005 | 0.85 | GPR119 (0.45) | — | |
| SCHEMBL2589683 | 0.80 | ACACB (0.55) | ACACBNPC1RAB9A | |
| SCHEMBL2583764 | 0.78 | HRH3 (0.42) | HRH3IKBKBACACBCHUKLTA4H | |
| SCHEMBL2775875 | 0.74 | HMOX1 (0.60) | IKBKBHMOX1ACACBSCD5 | |
| SCHEMBL2591704 | 0.74 | GPR119 (0.44) | HRH3ACACBLTA4HKDM4ENPC1 | |
| SCHEMBL7958453 | 0.73 | HRH3 (0.44) | HRH3ACACBLTA4H | |
| SCHEMBL8515255 | 0.71 | FFAR4 (0.38) | IKBKBHMOX1SCDCHUKSCD5 | |
| SCHEMBL4056560 | 0.71 | DGAT1 (0.47) | HMOX1 | |
| SCHEMBL17555503 | 0.71 | L3MBTL4 (0.43) | IKBKBHMOX1CHUKSCD5 | |
| SCHEMBL5267504 | 0.70 | HRH3 (0.43) | HRH3SCD5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2566860-B1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-10 | — | — | EP | disclosed |
| EP-2566860-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | Bristol-Myers Squibb Company (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
| WO-2011140160-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | GPR119, GPR139, GPR4 | HRH3 522/4885IKBKB 2127/4885HMOX1 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.